Regencell Bioscience Holdings experienced an unprecedented stock price surge of 64,000% within a week, fueled by retail mania and a 38-for-1 stock split that dramatically increased liquidity. Despite having no FDA approvals or revenue, speculative buying led to a peak market capitalization of $33 billion. Regulatory trading halts followed as the price plummeted 74%, stabilizing at a still-elevated valuation. The company focuses on Traditional Chinese Medicine therapies for neurocognitive disorders such as ADHD and autism.